Diagnostics For All

Still In Development Last Update: April 16, 2012
"Diagnostics for All", "D4A", "micrfluidic chip", "maternal neonatal innovation"

DFA Featured in Fast Company Magazine as one of the World's 50 Most Innovative Companies

Accurate, low-cost, point-of-care diagnostics for pregnant women and newborns are severely lacking in resource-limited rural settings. This leads to poor monitoring and late diagnoses of high risk pregnancies. To improve rural health care for expecting mothers and newborns, Diagnostics For All (DFA) proposes to develop two accurate, low-cost (<$0.10) postage stamp-sized paper-based diagnostics for expecting mothers and newborns that will be used to detect – and enable proper treatment of – (i) anemia and hyper/hypoglycemia and (ii) hypertensive disorders.

These point-of-care diagnostics require only a drop of blood or urine and require no additional steps beyond applying the sample. This means that they can be utilized by minimally-trained individuals in communities or clinics in rural settings to prevent unnecessary deaths during pregnancy and childbirth and improve the health of mothers and newborns through early detection of high-risk pregnancies and better patient management.